GENE ONLINE|News &
Opinion
Blog

2022-09-29| Trials & Approvals

Sanofi and Regeneron’s Dupixent Snags its Tenth Approval From the FDA

by Reed Slater
Share To
Dupixent, the monoclonal antibody jointly developed by Sanofi and Regeneron, is keeping its momentum going with its third FDA-approved indication this year and its tenth since 2017. The latest indication is reserved for adults with the chronic skin disease, prurigo nodularis, making it the first and only drug indicated for the disease. The FDA based its decision on two Phase 3 trials demonstrating clinically significant positive data. 

It's free! Log in now to read

LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!